Antiischemic effect of monophosphoryl lipid A in conscious rabbits with hypercholesterolemia and atherosclerosis

Z. Szilvássy, P. Ferdinándy, Christopher W. Cluff, Gary T. Elliott

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We studied whether monophosphoryl lipid A (MLA), an endotoxin derivative, protected the heart from planned ischemia in hypercholesterolemic conscious rabbits. Normal and hypercholesterolemic (8-week exposure to 1.5% cholesterol-enriched diet) conscious rabbits with right ventricular electrode and left ventricular polyethylene catheters were subjected to ventricular overdrive pacing (VOP; 500 beats/min over 10 min = control VOP). The resulting intracavitary ST-segment elevation, increase in left ventricular end-diastolic pressure (LVEDP), and a reduction of ventricular effective refractory period (VERP) were measured. Three days later the animals were given a single intravenous bolus of 10 or 30 μg/kg MLA or its solvent or both, and a second VOP (test VOP) was applied 24 h later. MLA decreased ST elevation and LVEDP increase from 2.1 ± 0.16 to 1.27 ± 0.25 and 0.97 ± 0.13 mV and 14.6 ± 1.2 to 11.1 ± 1.0 and 12.4 ± 1.2 mm Hg in normal animals and from 2.55 ± 0.14 to 1.31 ± 0.12 and 0.96 ± 0.30 mV and from 21.0 ± 1.6 to 11.7 ± 1.3 and 12.4 ± 1.3 mm Hg in atherosclerotic animals after 10- and 30-μg/kg doses, respectively (p <0.001 for each). VOP- induced VERP reduction was also significantly alleviated by both MLA doses; nevertheless, 30-μg/kg MLA significantly prolonged resting VERP with a slight VERP reduction in response to pacing in both normal and atherosclerotic animals. We conclude that MLA produces a delayed antiischemic effect in both normal and hypercholesterolemic/atherosclerotic conscious rabbits.

Original languageEnglish
Pages (from-to)206-212
Number of pages7
JournalJournal of Cardiovascular Pharmacology
Volume32
Issue number2
DOIs
Publication statusPublished - Aug 1998

Fingerprint

Hypercholesterolemia
Atherosclerosis
Rabbits
Blood Pressure
Polyethylene
Endotoxins
monophosphoryl lipid A
Electrodes
Ischemia
Catheters
Cholesterol
Diet

Keywords

  • MLA
  • Myocardial ischemia
  • Preconditioning mimetic
  • Ventricular pacing

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Antiischemic effect of monophosphoryl lipid A in conscious rabbits with hypercholesterolemia and atherosclerosis. / Szilvássy, Z.; Ferdinándy, P.; Cluff, Christopher W.; Elliott, Gary T.

In: Journal of Cardiovascular Pharmacology, Vol. 32, No. 2, 08.1998, p. 206-212.

Research output: Contribution to journalArticle

@article{32f03f0d1ec640ec95ba3c3b80e930f4,
title = "Antiischemic effect of monophosphoryl lipid A in conscious rabbits with hypercholesterolemia and atherosclerosis",
abstract = "We studied whether monophosphoryl lipid A (MLA), an endotoxin derivative, protected the heart from planned ischemia in hypercholesterolemic conscious rabbits. Normal and hypercholesterolemic (8-week exposure to 1.5{\%} cholesterol-enriched diet) conscious rabbits with right ventricular electrode and left ventricular polyethylene catheters were subjected to ventricular overdrive pacing (VOP; 500 beats/min over 10 min = control VOP). The resulting intracavitary ST-segment elevation, increase in left ventricular end-diastolic pressure (LVEDP), and a reduction of ventricular effective refractory period (VERP) were measured. Three days later the animals were given a single intravenous bolus of 10 or 30 μg/kg MLA or its solvent or both, and a second VOP (test VOP) was applied 24 h later. MLA decreased ST elevation and LVEDP increase from 2.1 ± 0.16 to 1.27 ± 0.25 and 0.97 ± 0.13 mV and 14.6 ± 1.2 to 11.1 ± 1.0 and 12.4 ± 1.2 mm Hg in normal animals and from 2.55 ± 0.14 to 1.31 ± 0.12 and 0.96 ± 0.30 mV and from 21.0 ± 1.6 to 11.7 ± 1.3 and 12.4 ± 1.3 mm Hg in atherosclerotic animals after 10- and 30-μg/kg doses, respectively (p <0.001 for each). VOP- induced VERP reduction was also significantly alleviated by both MLA doses; nevertheless, 30-μg/kg MLA significantly prolonged resting VERP with a slight VERP reduction in response to pacing in both normal and atherosclerotic animals. We conclude that MLA produces a delayed antiischemic effect in both normal and hypercholesterolemic/atherosclerotic conscious rabbits.",
keywords = "MLA, Myocardial ischemia, Preconditioning mimetic, Ventricular pacing",
author = "Z. Szilv{\'a}ssy and P. Ferdin{\'a}ndy and Cluff, {Christopher W.} and Elliott, {Gary T.}",
year = "1998",
month = "8",
doi = "10.1097/00005344-199808000-00006",
language = "English",
volume = "32",
pages = "206--212",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Antiischemic effect of monophosphoryl lipid A in conscious rabbits with hypercholesterolemia and atherosclerosis

AU - Szilvássy, Z.

AU - Ferdinándy, P.

AU - Cluff, Christopher W.

AU - Elliott, Gary T.

PY - 1998/8

Y1 - 1998/8

N2 - We studied whether monophosphoryl lipid A (MLA), an endotoxin derivative, protected the heart from planned ischemia in hypercholesterolemic conscious rabbits. Normal and hypercholesterolemic (8-week exposure to 1.5% cholesterol-enriched diet) conscious rabbits with right ventricular electrode and left ventricular polyethylene catheters were subjected to ventricular overdrive pacing (VOP; 500 beats/min over 10 min = control VOP). The resulting intracavitary ST-segment elevation, increase in left ventricular end-diastolic pressure (LVEDP), and a reduction of ventricular effective refractory period (VERP) were measured. Three days later the animals were given a single intravenous bolus of 10 or 30 μg/kg MLA or its solvent or both, and a second VOP (test VOP) was applied 24 h later. MLA decreased ST elevation and LVEDP increase from 2.1 ± 0.16 to 1.27 ± 0.25 and 0.97 ± 0.13 mV and 14.6 ± 1.2 to 11.1 ± 1.0 and 12.4 ± 1.2 mm Hg in normal animals and from 2.55 ± 0.14 to 1.31 ± 0.12 and 0.96 ± 0.30 mV and from 21.0 ± 1.6 to 11.7 ± 1.3 and 12.4 ± 1.3 mm Hg in atherosclerotic animals after 10- and 30-μg/kg doses, respectively (p <0.001 for each). VOP- induced VERP reduction was also significantly alleviated by both MLA doses; nevertheless, 30-μg/kg MLA significantly prolonged resting VERP with a slight VERP reduction in response to pacing in both normal and atherosclerotic animals. We conclude that MLA produces a delayed antiischemic effect in both normal and hypercholesterolemic/atherosclerotic conscious rabbits.

AB - We studied whether monophosphoryl lipid A (MLA), an endotoxin derivative, protected the heart from planned ischemia in hypercholesterolemic conscious rabbits. Normal and hypercholesterolemic (8-week exposure to 1.5% cholesterol-enriched diet) conscious rabbits with right ventricular electrode and left ventricular polyethylene catheters were subjected to ventricular overdrive pacing (VOP; 500 beats/min over 10 min = control VOP). The resulting intracavitary ST-segment elevation, increase in left ventricular end-diastolic pressure (LVEDP), and a reduction of ventricular effective refractory period (VERP) were measured. Three days later the animals were given a single intravenous bolus of 10 or 30 μg/kg MLA or its solvent or both, and a second VOP (test VOP) was applied 24 h later. MLA decreased ST elevation and LVEDP increase from 2.1 ± 0.16 to 1.27 ± 0.25 and 0.97 ± 0.13 mV and 14.6 ± 1.2 to 11.1 ± 1.0 and 12.4 ± 1.2 mm Hg in normal animals and from 2.55 ± 0.14 to 1.31 ± 0.12 and 0.96 ± 0.30 mV and from 21.0 ± 1.6 to 11.7 ± 1.3 and 12.4 ± 1.3 mm Hg in atherosclerotic animals after 10- and 30-μg/kg doses, respectively (p <0.001 for each). VOP- induced VERP reduction was also significantly alleviated by both MLA doses; nevertheless, 30-μg/kg MLA significantly prolonged resting VERP with a slight VERP reduction in response to pacing in both normal and atherosclerotic animals. We conclude that MLA produces a delayed antiischemic effect in both normal and hypercholesterolemic/atherosclerotic conscious rabbits.

KW - MLA

KW - Myocardial ischemia

KW - Preconditioning mimetic

KW - Ventricular pacing

UR - http://www.scopus.com/inward/record.url?scp=0344447040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344447040&partnerID=8YFLogxK

U2 - 10.1097/00005344-199808000-00006

DO - 10.1097/00005344-199808000-00006

M3 - Article

VL - 32

SP - 206

EP - 212

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 2

ER -